From October 27 to 28, the 2016 Huaxing Capital medical and life science and technology leader summit was held in the eastern suburb hotel of Shanghai. Starting from 2011, this is Huaxing's fourth summit in the field of medical and life science and technology. The theme of this summit is " towards the international community and embrace innovation". The two-day summit brought together nearly 400 top CEOs and investors from China and the United States in the medical and life science industries. They discussed the current situation and development of China's life and science industry, and shared their viewpoints, technological innovations and future development trends in the fields of medicine, biotechnology and other industries. Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the conference and make a thematic report for the conference.

At the meeting, Dr. Lu Xianping shared with the participants the original new drug development model and future development direction of CHIPSCREEN BIOSCIENCES. Founded in Shenzhen in 2001, CHIPSCREEN BIOSCIENCES has formed a number of original new drug product lines in major diseases such as tumors, metabolic diseases and autoimmune diseases, with the self-established " integrated drug discovery and early evaluation platform based on chemical genetics" as its core competitiveness. In 2014, original anti-tumor new drug Chidamide (Epidaza?) was approved for listing by China Food and Drug Administration (CFDA). At the same time, the company has realized the pace of synchronous global development of original Chinese medicines through the implementation of patent authorization to international pharmaceutical companies, the establishment of a business model of joint international clinical development and high-level cooperative research with multinational pharmaceutical enterprises.

In recent years, with the strong support of the state's major new drug discovery and thousand-person plan policies, a large number of returnees in the biomedical field have returned to China to set up enterprises, bringing with them the most advanced knowledge and experience in the development of new drugs in developed countries. Unprecedented intensive policies open the way for approval of innovative drugs; The attention and support given by the primary market is also very strong. Under many favorable factors, domestic drug companies have achieved major milestone results one after another. The era of innovative drugs in China will truly come in the next ten years.